Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI

Japanese Journal of Clinical Oncology

Volumn 39, Issue 9, 2009, Pages 569-575

  Naoki, Katsuhiko ^a,b   Kunikane, Hiroshi ^a   Fujii, Tomoki ^a   Tsujimura, Shuko ^a   Hida, Naoya ^a   Okamoto, Hiroaki ^a   Watanabe, Koshiro ^a  

^a YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Carboplatin; Non small cell lung cancer; Paclitaxel; Phase I; Weekly chemotherapy

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ANEMIA; ANGINA PECTORIS; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FEVER; HISTOPATHOLOGY; HUMAN; INOPERABLE CANCER; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PNEUMONIA; RECOMMENDED DRUG DOSE; SKIN TOXICITY; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PACLITAXEL; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 69949132919     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp059     Document Type: Article

References (34)

1. Carey DN. Chemotherapy in the management of patients with inoperable non-small cell lung cancer. Semin Oncol 1996;23(Suppl 16):71-5.
2. Sekine I, Nishiwaki Y, Watanabe K, Yoneda S, Saijo N. Phase II study of 3-hour infusion of paclitaxel in previously untreated stage III and IV non-small cell lung cancer. Clin Cancer Res 1996;2:941-5.
3. Furuse K, Naka N, Takada M, Kinuwaki E, Kudo S, Takada Y, et al. Phase II study of 3-hour infusion of paclitaxel in patients with previously untreated stage III and IV non-small cell lung cancer. West Japan Lung Cancer Group. Oncology 1997;54:298-303.
4. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007;18:317-23.
5. Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB. Cytotoxic studies of paclitaxel in human tumor cell lines. Br J Cancer 1993;68:1104-9.
6. Georgiadis MS, Russell EK, Gazdar AF, Johnson BE. Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations. Clin Cancer Res 1997;3:449-54.
7. Löffler TM, Freund W, Lipke J, Hausamen TU. Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: Results of a phase I/II trial. Semin Oncol 1996;23(Suppl 16):32-4.
8. Fennelly D, Aghajanian C, Shapiro F, O'Flaherty C, McKenzie M, O'Connor C, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997;15:187-92.
9. Akerley W, Glantz M, Choy H, Rege V, Sambandam S, Joseph P, et al. Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 1998;16:153-8.
10. Michel G, Leyvraz S, Bauer J, Aapro M, Stahel R, Alberto P. Weekly carboplatin and VM-26 for elderly patients with small-cell lung cancer. Ann Oncol 1994;5:369-70.
11. Kallab AM, Nalamolu Y, Dainer PM, Jillella AP. A phase II study of weekly paclitaxel and carboplatin in previously untreated patients with advanced non-small-cell lung cancer. Med Oncol 2005;22:145-51.
12. Jatoi A, Stella PJ, Hillman S, Mailliard JA, Vanone S, Perez EA, et al. Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (≥65 years of age); a phase II North Central Cancer Treatment Group Study. Am J Clin Oncol 2003;26:441-7.
13. Belani CP, Kearns CM, Zuhowski EG, Erkmen K, Hiponia D, Zacharski D, et al. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. J Clin Oncol 1999;17:676-84.
14. Gianni L, Kearns CM, Giani A, Capri G, Viganó L, Lacatelli A, et al. Non linear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995;13:180-90.
15. National Cancer Institute-Common Toxicity Criteria (NCI-CTC), Version 2.0. 30 April 1999.
16. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: Prospective evaluation of a formula based on renal function. J Clin Oncol 1989;7:1748-56.
17. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment (WHO Offset Publication No. 48). Geneva, Switzerland: Word Health Organization 1979.
18. Kearns CM, Gianni L, Egorin MJ. Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 1995;22(Suppl 6):16-23.
19. Glantz MJ, Choy H, Kearns CM, Cole BF, Mills P, Zuhowski EG, et al. Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. J Clin Oncol 1996;14:600-9.
20. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346:92-8.
21. Kelly K, Crowley J, Bunn PA, Jr, Presant CA, Grevstad PK, Moinpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplat in in the treatment of patients with advanced non-small cell lung cancer: A Southwest Oncology Group Trial. J Clin Oncol 2001;19:3210-8.
22. Scagliotti G, De Marinis F, Rinaldi M, Crino 'L, Gridelli C, Ricci S, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol 2002;20:4285-91.
23. Belani CP, Lee JS, Socinski MA, Robert F, Waterhouse D, Rowland K, et al. Randomized phase III trial comparing cisplatin -etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol 2005;16:1069-75.
24. Belani CP, Barstis J, Perry MC, La Rocca RV, Nattam SR, Rinaldi D, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003;21:2933-9.
25. Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable PS, et al. Randomized phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small cell lung cancer. J Clin Oncol 2008;26:468-73.
26. Socinski MA, Ivanova A, Bakri K, Wall J, Baggstrom MQ, Hensing TA, et al. A randomized phase II trial comparing every 3-weeks carboplatin/ paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Ann Oncol 2006;17:104-9.
27. Schuette W, Blankenburg T, Guschall W, Dittrich I, Schroeder M, Schweisfurth H, et al. Multicenter randomized trial for stage IIIB/IV non-small cell lung cancer using every-3-week versus weekly paclitaxel/ carboplatin. Clin Lung Cancer 2006;7:338-43.
28. Ramalingam S, Barstis J, Perry MC, La Rocca RV, Nattam SR, Rinaldi D, et al. Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin: Subanalysis of a randomized trial. J Thorac Oncol 2006;1:240-4.
29. Ramalingam S, Perry MC, La Rocca RV, Rinaldi D, Gable PS, Tester WJ, et al. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer. Cancer 2008;113:542-6.
30. Numico G, Colantonio I, Gasco M, Bertelli G, Garrone O, Occelli M, et al. Carboplatin and weekly paclitaxel in non-small cell lung cancer patients unfit for or pretreated with chemotherapy. Anticancer Res 2005;25:2555-60.
31. Pujol JL, Milleron B, Molinier O, Quoix E, Depierre A, Breton JL, et al. Weekly paclitaxel combined with monthly carboplatin in elderly patients with advanced non-small cell lung cancer: A multicenter phase II study. J Thorac Oncol 2006;1:328-34.
32. Hirabayashi M, Okuda M, Endoh K, Teramachi M, Yamaguchi K, Moriyama M, et al. Dose finding study of carboplatin and weekly paclitaxel for advanced non-small cell lung cancer. Jpn J Lung Cancer 2001;41:762-72.
33. Hirabayashi M, Endoh K, Teramachi M, Okuda M, Yamaguchi K, Fukuda K, et al. Phase II study of carboplatin and weekly paclitaxel combination chemotherapy in advanced non-small cell lung cancer: A Kansai Clinical Oncology Group Study. Lung Cancer 2004;44:355-62.
34. Kikuchi J, Yamazaki K, Kinoshita I, Asahina H, Imura M, Kikuchi E, et al. Phase I trial of carboplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 2004;34:505-9.